Continuous five‐day infusion of pala and 5FU: A pilot phase II trial

Cary A. Presant, Bach Ardalan, Phyllis Multhauf, Clara Chan, Russell Staples, Leland Green, Scott Browning, Brian I. Carr, Fong‐Fu ‐F Chang, William Thayer

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

In order to determine whether a simultaneous infusion of N-(phospho-n-acetyl)-L-aspartic acid (PALA) was able to increase the rate of antitumor response to 5-fluorouracil (5-FU), a pilot study was conducted. Of 10 evaluable patients with previously drug-untreated colorectal carcinoma, there were only two partial responses, lasting 2.3 and 1.6 months. No partial responses were observed in three evaluable patients with soft tissue sarcomas. The dose-limiting toxicity was dermatitis. The simultaneous infusion of PALA and 5-FU is not likely to produce a high number of antitumor responses of long duration in patients with colorectal carcinoma.

Original languageEnglish (US)
Pages (from-to)162-163
Number of pages2
JournalMedical and Pediatric Oncology
Volume11
Issue number3
DOIs
StatePublished - 1983
Externally publishedYes

Keywords

  • 5FU
  • PALA
  • chemotherapy
  • colon cancer

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Continuous five‐day infusion of pala and 5FU: A pilot phase II trial'. Together they form a unique fingerprint.

  • Cite this

    Presant, C. A., Ardalan, B., Multhauf, P., Chan, C., Staples, R., Green, L., Browning, S., Carr, B. I., Chang, FF. F., & Thayer, W. (1983). Continuous five‐day infusion of pala and 5FU: A pilot phase II trial. Medical and Pediatric Oncology, 11(3), 162-163. https://doi.org/10.1002/mpo.2950110305